Chronic granulomatous disease (CGD) is a rare inherited condition rendering neutrophils incapable of killing invading pathogens. This condition is due to the failure of a multicomponent microbicidal oxidase that normally yields a low-midpoint-potential b cytochrome (cytochrome bm). Although defects in the X chromosome-linked cytochrome account for the mijority of CGD patients, as many as 30% of CGD cases are due to an autosomal recessive disease. Of these, >90% have been shown to be defective in the synthesis of a 47-kDa cytosolic component of the oxidase. We demonstrate here in three unrelated cases of autosomal recessive CGD that the identical underlying molecular lesion is a dinucleotide deletion at a GTGT tandem repeat, corresponding to the acceptor site of the first intron-exon junction. Slippage of the DNA duplex at this site may contribute to the high frequency of defects in this gene.
MATERIALS AND METHODS
Cell Culture. B cell lines and HL-60 human promyelocytic leukemia cells were maintained at 37TC in Hepes-buffered RPMI 1640 medium/10%o fetal calf serum/2 mM L-glutamine/penicillin at 100 ,ug/ml/streptomycin at 100 pg per ml.
Induction of myeloid differentiation in HL-60 cells was by addition of 1% dimethyl sulfoxide to the culture medium and growth for a further 7 days.
Probe Construction. Probe constructs were made by digesting a complete cDNA cloned into the modified BlueScribe vector pVZ1 (12) with enzymes that cut once in the polylinker sequence 3' to the cDNA and once in the cDNA insert itself. When recircularized, this procedure generated five subclones all having the 5' end ofthe cDNA sequence but terminating at different 3' end points in the cDNA sequence. The T3 RNA promoter was thus brought into proximity with different regions of the cDNA for the synthesis of antisense cRNA probes. This nested set of subclones was converted to a series of overlapping probe templates covering distinct regions of the cDNA by linearizing the subclones at appropriate positions increasingly 5' within the cDNA inserts, as illustrated in Fig. 1 . The Bgl II probe did not require separate construction but was transcribed from the original Pst I probe by linearizing at the Bgl II site.
Abbreviations: CGD, chronic granulomatous disease; p47-phox, 47-kDa protein component of the microbicidal oxidase; AR-CGD, autosomal recessive CGD; X-CGD, X chromosome-linked CGD. *To whom reprint requests should be addressed. §The sequences reported in this paper have been deposited in the GenBank data base (accession nos. M60941 and M60942).
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RNase Mapping. Total RNA was isolated from EpsteinBarr virus-transformed B lymphocytes (13, 14) on guanidinium thiocyanate/cesium chloride gradients (15). For hybridization the RNA (1-4 pug) was mixed with 20 Ag of yeast tRNA and 4 ng of cRNA probe prepared by transcription of 1 ,ug of linearized vector with bacteriophage T3 polymerase and hybridized for at least 16 hr at 420C in siliconized glass capillary tubes. After hybridization, the contents of the capillary were flushed out and digested as described by Melton et al. (16) by using RNase A at 16.7 gg/ml and RNase T1 at 167 units/ml. The reaction products were analyzed on standard denaturing 5% polyacrylamide gels. The gel was then dried under vacuum and autoradiographed with x-ray film (Hyperfilm MP; Amersham) for up to 24 hr at room temperature or at -70'C with or without intensifying screens, depending on the strength of the signal.
DNA Amplification and Sequencing. Sequencing template was prepared from the total cell RNA by synthesis of cDNA using random hexanucleotide primers and PCR (30 cycles) with p47-phox-specific primers as described by Kawasaki and Wang (17) . PCR conditions were as follows: denature at 920C for 30 sec (1 min, 1st cycle); hybridize at 520C for 1 min; extend at 720C for 1 min (5 min final cycle). The PCR products were chloroform extracted (equal vol) and separated on a 0.8% high-gelling temperature/2.5% wide-range agarose composite gel. The DNA-containing gel slice was excised from the gel, frozen in liquid nitrogen (5-10 min), and thawed, and the DNA was then purified from the gel by centrifugation at 13,000 x g for 5 min. The eluate from the gel slice was collected into a 1.5-ml microcentrifuge tube, phenol/ chloroform/isoamyl alcohol (25:24:1) extracted once, and ethanol precipitated. The DNA was resuspended in 20-30 ,ul ofTE buffer (10 mM Tris, pH 8.0/1 mM EDTA), and 1 A.1 was used as template for sequencing reactions. The sequencing reactions were done as described by Keohavong and Thilly (18) but [32P]dCTP was used for labeling. The sequence was established on both strands of the DNA by using the PCR primers to prime the sequencing reactions. The genomic DNA subclone sequencing was performed as described in the Sequenase manual (United States Biochemical). Sequencing gel electrophoresis was done exactly as described for the RNase protection analysis.
RESULTS
RNase Protection Mapping of AR-CGD Lesion. To identify the molecular lesion rendering the p47-phox protein nonfunctional in AR-CGD patients, we first established that patients lacking the p47-phox protein did, indeed, express an mRNA. Epstein-Barr virus-transformed B cell lines have been shown to contain a functional oxidase identical to that of phagocytes (13, 14) and provided an abundant and convenient source of RNA from CGD patients and normal individuals. Northern (RNA) blot hybridizations of the patients' RNA, probed with the insert from a complete p47-phox cDNA clone (12) revealed the presence of an mRNA corresponding identically in size to the normal p47-phox messenger (C.M.C., unpublished work) in agreement with observations made in monocytes (8). Clearly, the defect in AR-CGD patients did not involve RNase protection analysis of RNA from normals and AR-CGD patients. (a) Total cellular RNA was hybridized in solution to a 32P-labeled cRNA probe, and the resulting hybrids were digested with a mixture of RNases A and T1. To control for equal loading of RNA the Pst I probe was used in combination with an unrelated constitutive gene probe, that for cofilin, which was included in the same hybridization reactions as the p47-phox protein probe. The cofilin probe was prepared from a subclone encoding the 5' 250 nt of the cDNA. Arrows denote the protected probe species; positions of the full-length protection products are given by the protection products in lanes 10 and 11. The slight size discrepancy between size of the protected species in lanes 10 and 11 and those in the remaining lanes is from the vector sequences common to the probe and the synthetic mRNA, which are absent in the RNA extracted from cells. The fully protected Pst I probe probably appears as a doublet due to initiation of mRNA at two slightly differing sites. Other probes [used here (Acc I, see below) and previously (12)] also complementary to the 5' terminus of the mRNA have behaved similarly. The arrow (47 kDa) at 220 nt indicates the position ofa p47-phox-specific partial-protection product, which is the only species seen with the AR-CGD RNA. Note that in uninduced HL-60 cells, which express only very small amounts of p47-phox, this species, as well as the full-length product, are absent, demonstrating their common origin. Lane designation is as follows: RNA from X-CGD heterozygote carrier ( Proc. Nati. Acad. Sci. USA 88 (1991) 2755 deletion of the entire gene or gross structural rearrangements but was due to a more subtle alteration' in coding potential. With the object of locating such a change in the mRNA sequence, a series of RNase mapping experiments (16) were done. The cDNA sequence was divided into four subclones (see Materials and Methods), together covering the complete mRNA sequence, except for m100 nt (positions 635-726 and 319-342) (see Fig. la) . These four 'subclones were transcribed into cRNA probes (16) by using the vector-encoded bacteriophage T3 promoter and hybridized in solution to total cellular RNA from normal individuals, X chromosome-linked CGD (X-CGD) patients, or AR-CGD patients. After RNase digestion of the RNA/RNA hybrids'and denaturing gel electrophoresis, only the Pst I probe, which contained sequences complementary to the 5' terminal 318 nt of the mRNA, showed evidence for discriminating between AR-CGD and normal p47-phox mRNA. Results obtained with this probe are shown in Fig. 2a , where the hybridizations also contain a constitutive control gene probe, that for the actinbinding protein cofilin (19) . In all three cases of AR-CGD virtually no fully protected (318 nt) probe was visible; instead a partial protection product of -220 nt was seen indicating a divergence in sequence between the probe and AR-CGD mRNA s100 nt from one end of the Pst I probe. We note that the' size of this partial product also corresponds with a similar partial protection product visible in all the "wild-type" cellular RNAs, including that from the HL-60 promyelocytic cell line. This signal probably derives from a combination of the presence of unprocessed nuclear RNA, some incorrectly spliced mRNA, and possibly also slippage of the two strands in the hybrid (see below).
Owing to the uniform labeling of the probe it was not possible to locate unequivocally the position of the sequence difference between the normal and AR-CGD cases. To define this difference in greater detail, a series of additional probes was prepared, complementary to different areas of the region of the mRNA encompassed by the Pst I probe (Fig. lb) . The Bgl II probe proved unable to distinguish AR-CGD patients' RNA from normal RNA (data not shown), which indicated that the defect in the AR-CGD patient's p47-phox mRNA could not be located in the region of overlap between the Bgl II and Pst I probes but was, therefore, located within 100 nt ofthe 5' end ofthe mRNA. This pattern was confirmed by use of the Acc I probe, which spans the 5' terminal 142 nt of the mRNA, in contrast with the Bgl II probe, and behaved similarly to the Pst I probe in revealing a clear difference between AR-CGD and normal (or X-CGD) p47-phox mRNA (Fig. 2b) . With this probe a strong partial protection product (95-100 nt in length) was observed with AR-CGD, but no full-length species of 142 nt. This technique located the AR-CGD defect to a position :'45-50 nt from one end of the Acc I probe. As the AR-CGD defect had been mapped to 100 nt from the 5' end of the mRNA using the Pst I probe, it was highly probable that the partial-protection product from the Acc I probe was missing sequences from the 3' end of the probe. This result would then also place the AR-CGD lesion at -100 nt into the mRNA. This interpretation was confirmed by using the Xmn I probe, which spans the first 70 nt ofthe p47-phox mRNA. As expected, the Xmn I probe was unable to detect any sequence discrepancy between normal and AR-CGD p47-phox mRNA, although the probe was clearly able to accurately identify accumulation of this mRNA during (dimethyl sulfoxide-induced) myeloid differentiation in HL-60 cells (data not shown) (7, 12).
DNA Sequence Analysis of AR-CGD. The localization of the defect in AR-CGD to approximately position 100 in the mRNA enabled us to elucidate the sequence of the mRNA by direct sequencing of a PCR-amplified partial cDNA (Fig. 3a) . A PCR product that spanned the defect was obtained by synthesizing oligonucleotide primers identical to the extreme 5' end of the mRNA sequence and at a location overlapping the Bgl II site (position 170). After reverse transcription, these primers were able to direct the synthesis of a PCR product of 178 nt (Fig. 3b) . The PCR product was purified, and its sequence was determined (Fig. 3a) . In all three cases of AR-CGD a GT dinucleotide at a GT-GT repeat was found deleted from the sequence at positions 95 and 96 (see also Fig.  3b ). The consequences of this 2-nt deletion are (i) to frameshift the mRNA such that amino acids subsequent to amino acid 24 are incorrect and (ii) to introduce a chain-terminating codon (TAA) at amino acid 52 (nt 175-177). This alteration predicts a protein product of m6000 Mr from the AR-CGD p47-phox mRNA (Fig. 3b) . At present we have no evidence regarding the existence of such a molecule in the cells from AR-CGD patients.
Localization of the AR-CGD defect to this position in the mRNA was of interest as our analysis of genomic DNA by Southern blotting (H.B.-G and C.M.C., unpublished data) had indicated the presence of an intron-exon junction close to the Xmn I site and upstream from the Acc I site. DNA sequencing of a genomic subclone demonstrated that the AR-CGD deletion lay exactly at this junction (Fig. 4) , which comes at position 94/95 in the wild-type mRNA sequence (Fig. 3b) . The The sequence of this 224-nt PCR product was do identical fashion to the mRNA amplification I quencing revealed that the genomic DNA from t patients also lacked the GT dinucleotide found r the mRNA (Fig. 4) (20) . At present we have no definitive answer GTGT repeat in the gene for p47-phox should b tible to mutation. IC seems unlikely that the maintained in any way by selection or confers al gote advantage, as appears to be the case in the t (21) and in cystic fibrosis (22) . It is possible t intrinsic to the DNA sequence might render it su deletion. Dinucleotide repeats have been cited ( genic, and a brief literature search has revealed 1 cases (24, 25) , the most obvious parallel to the p4 deletion being in a particular case of a-thalasse this instance the lesion was found at an AGAG donor site of the first intron-exon junction. Also with the gene defect for p47-phox, repetition of th nucleotides at the splice junction prevents the g an abnormal splice in the deleted mRNA. A simi has also been found in a c-myc cDNA clone (27) 
